Histone post-translational modifications recruit bromodomain-containing proteins such as BRPF1 to chromatin, but it is unknown how multiple modifications modulate acetyllysine binding.
INTRODUCTION
In the human genome, DNA accessibility and transcriptional activation is often regulated by post-translational modifications (PTMs), among which acetylation of lysine residues on histones plays a major role. Histone acetylation enhances DNA accessibility by loosening the compact conformation of chromatin and by recruiting transcription and chromatin remodeling factors to increase transcriptional activity 1, 2 . Bromodomains, which are epigenetic reader domains that specifically recognize ε-N-acetylated lysine residues on histone tails, are known to be important regulators of chromatin remodeling and transcriptional activation 3 . A total of 61 unique bromodomains are known to exist in 46 different bromodomain-containing proteins, and these bromodomains have been grouped into eight major families on the basis of sequence and structural homology 4 . Mutation and aberrant expression of bromodomain-containing proteins has been associated with multiple types of cancer, inflammation, neurological disorders and metabolic diseases. Importantly, bromodomains are often found in chromatin-modifying complexes, whose activity can lead to the altered expression of genes that drive these diseases in humans 5 .
Bromodomain-PHD finger protein 1 (BRPF1) is known to play a role in maintaining the expression of genes involved in several developmental processes and hematopoiesis [6] [7] [8] . The BPRF1 protein is a unique, multivalent chromatin reader which contains an N-terminal plant homeodomain (PHD)-zinc-knuckle-PHD (PZP) module, a bromodomain for acetyllysine recognition, and a C-terminal proline-tryptophan-tryptophan-proline (PWWP) domain 9 . The Nterminal motif I of BRPF1 interacts with monocytic leukemic zinc finger (MOZ) and MOZrelated factor (MORF), while the downstream motif II interacts with inhibitor of growth 5 (ING5) and the MYST/Esa1-associated factor 6 (MEAF6) 10 . Thus, an important function of BRPF1 is to bridge the association of MOZ and MORF with ING5 and MEAF6, where it is an important regulator of many cellular processes including the self-renewal of leukemic stem cells 8 , embryo development and cell proliferation 11 , and osteoclast differentiation 12 through its activity with MOZ and MORF 8 . BRPF1 enhances the acetyltransferase activity of the MOZ/MORF HATs via interaction with the histone acetyltransferase domain 10 , and also bridges the enzymatic complex to specific post-translational modifications in chromatin 13 .
Post-translational modifications (PTMs) on histones are known to be crucial for the regulation of chromatin and DNA accessibility 14 . PTMs modulate signal transduction pathways to recruit effector molecules, such as readers of histone modifications to chromatin 15 . These histone reader domains direct biological outcomes based on the cellular context of the modifications 16 . In humans, proteins are known to undergo a number of PTMs, including but not limited to phosphorylation, methylation, acetylation and ubiquitination, that greatly influence their function in cellular events 17 . Specifically, histone acetylation is an important component of epigenetic signaling, in that it weakens the interactions of histones with DNA by decreasing nucleosome compaction 18 , regulates enzymatic activity, and mediates the localization of macromolecular complexes to histones through bromodomain-containing proteins 19 . Therefore, the recognition of acetylated lysine by bromodomains has broad implications for cellular events including chromatin remodeling and transcriptional activation 20 .
The postulation that aberrant chromatin acetylation by MOZ may be a contributing factor to the development of cancer and other diseases was first demonstrated by cloning the breakpoint-associated genes of the recurrent t(8;16)(p11;p13) translocation in patients with a subtype of acute myeloid leukemia (AML) 21 . This translocation results in a novel fusion that combines the PHD finger motifs and MYST acetyltransferase domain of MOZ, with an intact CREB-binding protein (CBP), suggesting that the MOZ-CBP fusion protein gives rise to leukemogenesis through chromatin hyperacetylation 21 . Since BRPF1 plays a crucial role in the MOZ/MORF complex, and their interaction domains remain intact after the translocation, it may also be implicated in the diseases in which MOZ and MORF are known to play a role. The MOZ gene has been reported to be mutated in esophageal adenocarcinoma 22 , while the MORF gene has been reported to be disrupted in leiomyomata 23, 24 , mutated in familial breast cancer 25 , and altered in castration-resistant prostate cancer 26 . Deletion of the mouse BRPF1 gene showed that BRPF1 is crucial for the growth and proliferation of embryonic fibroblasts and hematopoietic progenitors 11 . Also, multiple mutations in the BRPF1 gene have been reported to give rise to neurodevelopmental disorders due to a deficiency in histone H3K23 acetylation, supporting evidence that BRPF1 acts through MOZ and MORF to modulate chromatin modification states 7 .
The BRPF1 bromodomain belongs to the family IV bromodomains, which also include the BRPF2, BRPF3, BRD7, BRD9, ATAD2 and ATAD2B bromodomains based on their sequence and structural homology 4 . Bromodomains share a conserved globular fold and are composed of a left-handed bundle of four α-helices Z, A, B and C. The helices are linked by loops of variable length (ZA and BC loops), which form the hydrophobic acetyllysine (Kac) binding pocket 4 . The acetyllysine recognition of these bromodomains differ mainly due to the variability within their ZA and BC loops 4 .These differences, have also permitted the development of small molecule inhibitors with selectivity for specific bromodomains within the same family [27] [28] [29] [30] .
An earlier study characterized the interaction of the BRPF1 bromodomain with mono-acetylated ligands on the N-terminal of histone tails, and showed it selects for multiple acetylation modifications including H2AK5ac, H4K12ac and H3K14ac 31 . However, each of the four histone proteins can be post-translationally modified at multiple locations, and with several different chemical marks 32 . Proteomic studies have demonstrated that each histone tail caries a unique set of modifications 33 , and that the abundance and availability of specific histone proteoforms is dynamic 34, 35 . The BET bromodomains BRD2, BRD4 and BRDT are all able to bind diacetyllysine modifications including H4K5acK8ac, H4K5acK12ac and H4K12acK16ac 4, 36 .
Other family IV bromodomains, including the BRD9 and ATAD2 bromodomain, are able to interact with di-acetylated histone ligands such as H4K5acK8ac and H4K5acK12ac, respectively 19, 37 . However, it has not been established if the BRPF1 bromodomain can recognize di-acetyllysine modifications, or how multiple histone marks modulate acetyllysine recognition.
Previously published data on the BRPF1 bromodomain revealed that it recognizes several acetylated lysine residues on N-terminal histone tails 31 . Related bromodomain proteins have been observed to cooperatively bind histone peptides with di-acetyllysine marks, through accommodation of the two acetyllysine residues in the same bromodomain binding pocket. For example, the BRDT bromodomain BD1 in the bromodomain and extra-terminal domain (BET) family, recognizes the di-acetylated histone ligand H4K5acK8ac 36 . Other bromodomain proteins in the BET family including BRD2 and BRD4 are also known to recognize di-acetylated histone ligands, mainly through their enlarged binding pockets 4 . Three-dimensional X-ray crystal structures of the BAZ2A and BAZ2B bromodomains in family V have also been solved in complex with H4K16acK20ac and H4K8acK12ac di-acetylated histone ligands 38 . In addition, the recognition of diacyl-modified histone ligands by the BRD9 bromodomain in family IV has been structurally characterized 19 . However, the binding and recognition of di-acetylated histone ligands by the BRPF1 bromodomain has yet to be fully elucidated.
In this study we characterized the binding affinity of the BRPF1 bromodomain with multiple diacetylated histone ligands by isothermal titration calorimetry (ITC). We show that the BRPF1 bromodomain binds preferentially to histone peptides H4K5acK8ac and H4K5acK12ac. We utilized nuclear magnetic resonance (NMR) chemical shift perturbation techniques to map the BRPF1 bromodomain binding pocket and identify important residues involved in di-acetyllysine recognition. We performed site-directed mutagenesis experiments, together with ITC and analytical ultracentrifugation (AUC) experiments to evaluate the relative contribution of specific amino acid residues in di-acetyllysine coordination. We also tested how adjacent PTMs impact acetylysine recognition. The results provide new insights on how the BRPF1 bromodomain selects for its di-acetyllysine histone ligands at the molecular level, and how the combinatorial action of post-translational modifications can influence BRPF1 bromodomain binding and specificity. Our study further supports current research efforts geared toward the development of novel therapeutics targeting the BRPF1 bromodomain in acute myeloid leukemia.
RESULTS

The BRPF1 bromodomain recognizes di-acetyllysine histone modifications
We postulated that the BRPF1 bromodomain may be able to recognize di-acetylated histone ligands similarly to the closely related family IV bromodomain BRD9, which has been shown to recognize multiple diacyl modifications on histone H4K5/K8 19 . To investigate our hypothesis, we sought to further characterize the histone ligands of this bromodomain by performing ITC experiments with mono-and di-acetylated lysine residues on the histone H4 peptide ( Table 1 and Figure 1) . The mono-acetylated histone H4K5ac peptides (residues 1-10 and 1-15) bound the strongest, out of the mono-acetylated peptides tested, with dissociation constants (KDs) of 60.1 ± 6.8 µM and 79.3 ± 4.5 µM. The BRPF1 bromodomain also bound H4K8ac (1-10),
H4K12ac (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) and H4K16ac (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) with KDs of 168.4 ± 4.7 µM, 97.3 ± 4.0 µM and 464.3 ± 1.7 µM, respectively. Interestingly, when the ITC experiment was performed with the diacetylated H4K5acK8ac (1-10) peptide the BRPF1 bromodomain bound with a dissociation constant about two-fold stronger than that of the mono-acetylated H4K5ac peptide (26.7 ± 1.8 µM). Similarly, we found that the combination of H4K5acK12ac marks improved the BRPF1 bromodomain binding affinity six-fold over the recognition for the singly acetylated H4K12ac mark with a KD of 52.0 ± 2.9 µM, which is also slightly stronger than the single H4K5ac modification. However, other combinations of di-acetylation marks on the histone tail decreased the binding affinity with the BRPF1 bromodomain. The addition of acetylation at lysine 16 in the H4K5acK16ac ligand resulted in a binding affinity of 92.1 ± 7.1 µM, while the H4K8acK16ac bound at 572.8 ± 14.6 µM. The H4K12acK16ac ligand bound with the weakest affinity of 705.6 ± 6.0 µM, while the combination of H4K8acK12ac abrogated the binding interaction.
Interestingly, when compared to our previous results with the BRPF1 bromodomain, inclusion of residues 1-3 on the histone tail also improves the binding interaction with histone H4 peptides that contain the K5 or K8 acetyllysine modification. Thus, the H4K5ac peptides (residues 1-10 or 4-17) bind with KDs of 60.1 ± 6.8 µM and 1236 µM, respectively ( Table 1) , while the H4K8ac peptides (residues 1-10 or 4-17) bind with KDs of 168.4 ± 4.7 µM and 697 µM, respectively 31 . However, the peptides with the H4K12ac modification (residues 4-17 or 1-15) had similar binding constants of 86.1 ± 9.1 µM and 97.3 ± 4.0 µM, respectively. This data indicates that residues 1-3 on the N-terminus of histone H4 tail are important for recognition of acetyllysine modifications near the N-terminus of this histone, while recognition of modifications further downstream are not mediated by the N-terminal residues. Furthermore, this is the first direct evidence that the BRPF1 bromodomain can read a span of 8-10 amino acid residues on the histone tail.
Since previous studies have shown that the BRPF1 bromodomain recognizes the H3K14ac
histone peptide, we also tested the binding affinity of this bromodomain with mono-and diacetylated peptides containing the first 24 amino acid residues of human histone H3. Earlier ITC experiments done with the H3K14ac (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) and H3K9ac (1-12) peptides had KDs of 626 µM, and no binding, respectively 31 . Our current ITC experiments on the H3K14ac (1-24) and
H3K9ac peptides revealed that these ligands have dissociation constants of 182.7 µM and 751.1 µM, respectively. A dissociation constant of 233.8 µM was obtained for the H3K9acK14ac (1-24) di-acetylated histone peptide, which indicates that the acetylation mark at K9 impairs the ability of the BRPF1 bromodomain to bind H3K14ac (Table 1, Figure 1 ). Taken together, our results in Table 1 show that the BRPF1 bromodomain is able to recognize diacetyllysine modifications over a span of 8-10 amino acids on the histone tail, which suggests it may be important for the effector-mediated recognition of histone proteins bearing multiple modifications.
Thermodynamics of di-acetylated histone ligand binding to the BRPF1 bromodomain
To further understand the binding mechanism driving recognition of mono-and di-acetylated histone ligands by the BRPF1 bromodomain, we investigated the thermodynamic parameters obtained from our ITC data. The ΔH and ΔS values calculated for the BRPF1 bromodomain interaction with various mono-and di-acetylated histone ligands are shown in Table 1 , and reflect how the enthalpic and the entropic terms contribute to the binding affinity (KD). Larger, negative changes in enthalpy (ΔH) were observed upon binding of the di-acetylated histone ligands to the BRPF1 bromodomain as compared to the mono-acetylated histone ligands.
Amongst the di-acetylated histone ligands, H4K5acK8ac (1-10) and H4K5acK12ac (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) showed not only the most negative ΔH values, but also the highest binding affinities KD = 26.7 ± 1.8 µM and 52.0 ± 2.9 µM, respectively, indicating that more energetically favorable electrostatic and van der Waals interactions form with these ligands. The change in entropy (ΔS) to more negative values observed upon BRPF1 bromodomain binding to the di-acetylated histone ligands is also suggestive of favorable conformational changes that occur during the complex formation. In contrast, the mono-acetylated histone ligands showed more positive ΔH values and ΔS values, supporting a less favorable interaction of these peptides with the BRPF1 bromodomain.
Crosstalk between PTMs modulate acetyllysine recognition by the BRPF1 bromodomain
To determine how the combinatorial action of PTMs on the histone tail modulates acetyllysine recognition, we performed ITC experiments to observe how the in vitro binding affinity of the BRPF1 bromodomain for acetylated histone peptides would change if other modifications are located adjacent to the acetyllysine (Kac) recognition site ( Table 1 and Figure 1 ). The BRPF1 bromodomain recognized the H4K5ac (1-15) mono-acetylated histone peptide with a binding affinity of 79.3 µM, but binding decreased by approximately three-fold (KD = 228.5 µM) when serine 1 of histone H4 was phosphorylated. The BRPF1 bromodomain also recognizes the H4K12ac (1-15) peptide with a binding affinity of 97.3 µM, and the affinity is decreased by ~1.5-fold (169.6 µM) when lysine 5 was tri-methylated. Interestingly, tri-methylation of lysine 12 in combination with acetylation of lysine 5 did not significantly alter the affinity of the BRPF1 bromodomain for the H4K5ac (1-15) histone ligand, indicating that the H4K12me3 mark is permissive for H4K5ac recognition. Together, our results show that crosstalk between adjacent PTMs on the histone tail modulate how acetyllysine is recognized by the BRPF1 bromodomain.
The BRPF1 bromodomain recognizes di-acetylated histone ligands as a monomer
As shown in Table 1 , the N value observed in all of our ITC data indicates that the BRPF1 bromodomain interacts with modified histone H3 and H4 tails as a monomer. To confirm this, we also performed analytical ultracentrifugation sedimentation velocity experiments to determine the molecular mass of this bromodomain in complex with mono-and di-acetylated histone ligands. The molecular weight of the apo BRPF1 bromodomain is 13,703 Da, while the molecular weights of the histone ligands tested range from 958-1371 Da. Strikingly, the signal peaks of the BRPF1 bromodomain alone, or in complex with its mono-and di-acetylated histone ligands, overlap at approximately 14-15 kDa (Figure 2) . These results support our ITC data showing that the BRPF1 bromodomain recognizes both mono-and di-acetylated histone ligands as a monomer in solution.
Characterization of the BRPF1 bromodomain binding pocket by NMR
To outline specific amino acid interactions in the BRPF1 bromodomain binding pocket with the mono-and di-acetylated histone peptides, two-dimensional, 1 H-15 N heteronuclear single quantum coherence (HSQC) NMR experiments were performed. We previously reported the backbone assignments for the BRPF1 bromodomain accomplished by means of multidimensional NMR spectroscopy 31 
Mutational analysis identifies residues that may coordinate the second acetyllysine moiety
To obtain more information about coordination of di-acetyllysine by the BRPF1 bromodomain we used site-directed mutagenesis coupled to ITC binding assays ( Table 2 and supplemental Fig S1) . To investigate whether both acetyllysine groups in the di-acetylated histone ligands are accommodated in the canonical BRPF1 bromodomain binding pocket, or if secondary binding contacts exist on the BRPF1 bromodomain, we carefully chose six amino acid residues (T24, N26, E30, E36, K81, R91) to mutate to alanine. Amino acid residues T24 and R91 were mutated to test the possibility of an additional binding surface that was shown to coordinate H3K14ac between the αZ and αC helices as observed for the ATAD2 bromodomain 39 . N26 was mutated to probe the differences in its chemical shift perturbation pattern in the presence of the monoacetylated H4K5ac (1-15) ligand versus the di-acetylated H4K5acK12ac (1-15) ligand in our NMR chemical shift data (Figure 3E-F) . E30 was chosen based on its proximity to the N-1,3-
small molecule inhibitor seen in the acetyllysine binding site of the BRPF1 bromodomain crystal structure 4UYE 40 . E36 was predicted to make side chain interactions with lysine 8 on histone H4 during a molecular dynamic simulation of the ATAD2 bromodomain in complex with the H4K5acK12ac ligand 41 . Lastly, the K81 residue was mutated because of its proximity to lysine 8 in our published structure of the BRPF1 bromodomain in complex with its H4K12ac ligand (PDBID: 4QYD) 42 . We performed circular dichroism (CD) experiments on the mutant BRPF1 bromodomain proteins ( Table 3 and Figure 4 ) to ensure they were properly folded, and we ran ITC binding experiments to test the binding affinities of the BRPF1 bromodomain mutants in combination with H4K5ac (1-10), H4K12ac (1-15), H4K5acK8ac (1-10) and H4K5acK12ac (1-15) histone ligands. These experiments were designed to test our hypothesis that if the second acetyllysine group is coordinated via specific side-chain interactions on the BRPF1 bromodomain, then mutating it should decrease the binding affinity to what is seen for the singly acetylated histone ligands. The binding affinities with observed stoichiometries of the mutant BRPF1 bromodomains for the histone ligands tested are shown in Table 2 . The ITC traces of the mutant BRPF1 bromodomains with their histone ligands are located in Supplemental Figure   S1 . Interestingly, all of the alanine mutations to the BRPF1 bromodomain caused an increase in binding affinity for the H4K5acK12ac ligand, while most of these mutations caused at least a slight decreased in binding affinity for H4K5acK8ac. Our mutational study did not cause the binding affinity of di-acetylated ligands to revert to singly acetylated ligand values, but the T24A, E36A and K81A mutations did show a weakened binding interaction between the BRPF1 bromodomain and the H4K5acK8ac ligand. The N26A mutation decreased the affinity for the H4K12ac (1-15) ligand. and increased the binding affinity for the H4K5acK12ac (1-15) and
H4K5ac (1-10) ligands, but it did not have a large effect on binding of the H4K5acK8ac (1-10) ligand. The remaining mutations either caused no significant difference in the binding interaction, or resulted in increased binding affinities with the BRPF1 bromodomain. The inconsistent binding affinity of BRPF1 mutants suggests that multiple residues are involved in coordinating the second acetyllysine group.
The role of ordered water in bromodomain structure and histone ligand coordination
We made a conservative change to Y40 by mutating the residue to a phenylalanine in order to investigate how loss of water coordination would impact acetyllysine recognition. The BRPF1 Y40F bromodomain variant was unable to bind mono-or di-acetylated histone ligands ( Table 2 and Figure 5 ), and surprisingly loss of the ordered water molecule also resulted in significant changes in the bromodomain secondary structure. As seen in Table 3 , the alpha helical content of the BRPF1 Y40F bromodomain mutant was reduced from 94% to 43%, while the beta strand content increased from almost zero to 18%. Thus, it appears that ordered water in the bromodomain binding pocket is not only important for the recognition of acetylated histone ligands, but it also plays a key role in maintaining the 3D fold of the bromodomain module.
DISCUSSION
Previous studies on the BRPF1 bromodomain revealed that it recognizes several acetylated lysine residues on the N-terminus of histone tails 31 . The BRPF1 bromodomain preferentially selects for acetylation modifications on the histone H4 tail, including histone H4 acetylated at lysine 5 (H4K5ac), and lysine 8 and lysine 12 (H4K8ac and H4K12ac). However, BRPF1 is also able to recognize the histone H3 and H2A ligands H3K14ac and H2AK5ac 31 . More recently it has been discovered that bromodomain-containing proteins such as BRD2, BRD3 and BRD4 can bind to histone ligands with di-acetyllysine marks 43 . Another example of this is the first bromodomain (BD1) in the bromodomain testis specific protein (BRDT), which is a member of the bromodomain and extra-terminal domain (BET) subfamily. BRDT BD1 failed to recognize mono-acetylated histone H4 tails, but was able to bind multiple di-acetylated histone H4 peptides as well as tetra-acetylated histone H3 peptides 36 . BRDT BRD1 recognizes the di-acetylated histone ligand H4K5acK8ac with a low micromolar affinity, and the crystal structure of the BRDT BD1 in complex with this ligand demonstrated the 'wide pocket' of the BRDT BD1 bromodomain is able to accommodate both acetylated lysine residues within the canonical bromodomain binding pocket 36 . This is opposed to the 'keyhole pocket' of the yeast GCN5 bromodomain, which is only able to fit one acetyllysine group inside the binding pocket at a time. Coordination of di-acetyllysine by the first bromodomain in the BET subfamily appears to be conserved as demonstrated by ligand binding assays with BRD1 and BRD2 44, 45 , as well as structures of BRD4 BD1 with H4K5acK8ac and H4K12acK16ac (PDBIDs 3UVW and 3UVX, respectively) 4 . It has been suggested that other bromodomain protein families can recognize diacetylated histone ligands as well, possibly through alternative binding modes. The structures of the BAZ2A and BAZ2B bromodomains have been solved with the di-acetylated histone H4 ligands H4K16acK20ac and H4K8acK12ac, respectively (PDBIDs 4QBM and 4QC3) 38 . In these structures, BAZ2A is able to coordinate the di-acetylated ligand as a monomer, much like the BET family bromodomains, while the BAZ2B bromodomain forms a dimeric complex to coordinate the H4K8acK12ac histone ligand.
In this study, we show the BRPF1 bromodomain is able to selectively recognizes multiple histone mark combinations and binds preferentially binds to di-acetylated ligands on the Nterminus of histone H4. The results from our ITC binding assays demonstrate that this bromodomain is capable of recognizing several di-acetylated histone ligands and has the highest affinity for the histone H4K5acK8ac ligand, followed by the H4K5acK12ac ligand. Our results also show that the interaction of the BRPF1 bromodomain interaction with histone ligands is enthalpy-driven. A similar result was also observed for the BRPF1 bromodomain with smallmolecule ligands, and with the ATAD2 bromodomain-ligand complexes 46, 47 . The enthalpy (ΔH) and entropy (ΔS) changes obtained from fitting the binding isotherm illustrate the mechanism driving the protein-ligand interaction 48 . A tight binding interaction typically arises from several favorable associations (mostly noncovalent) between the protein and the ligand, thus resulting in a large negative change in enthalpy while also accompanied by a negative entropy change due to restricted mobility of the interacting partners 48, 49 . Thus, the larger, more negative enthalpy and entrophy changes induced upon binding to the H4K5acK8ac and H4K5acK12ac ligands, as compared with the mono-acetlylated ligands, supports the formation of a stronger, more stable complex with these ligands.
We also tested the histone H4K5acK16ac and H4K8acK16ac ligands and found that these diacetyllysine combinations weakened the BRPF1 bromodomain interaction with the histone tail.
Examination of the histone H3/H4 proteoforms found in human cancer cell lines revealed that in promyelocytic leukemia cells (HL60) the H4K5acK16ac mark is down-regulated, while it is upregulated in acute promyelocytic (NB4) cells 50 . Additionally, the H4K8acK16ac mark was down-regulated in all leukemia cell lines tested. Thus, as histone PTMs are altered in disease states, the availability of particular acetyllysine combinations will enhance or inhibit the interaction of BRPF1 with chromatin and influence recruitment of the MOZ/MORF HAT complex.
Results from our previous study demonstrated that the BRPF1 bromodomain recognizes the singly-acetylated histone ligands H2AK5ac, H4K12ac, H4K8ac, H4K5ac and H3K14ac respectively 31 . Our current results demonstrate the BRPF1 bromodomain preferentially binds to the H4K5ac modification on singly acetylated histones, which is likely the predominant interaction driving recognition of di-acetylated ligands. Interestingly, the ITC binding data show that the BRPF1 bromodomain functions as a di-acetyllysine reader, with a binding pocket able to recognize PTMs over span of 8-10 residues on each histone tail. Additionally, the BRPF1 bromodomain interacts with mono-and di-acetylated histone ligands as a monomer in solution based on the binding stoichiometry (N: peptide-to-bromodomain ratio) observed in the ITC binding assays and confirmed in AUC experiments. A study on the family IV BRD9 bromodomain indicated that it binds to the histone H4K5acK8ac ligand with an ITC N-value of 0.44, suggesting a dimeric interaction with two bromodomains bound to one histone peptide 19 .
The family IV bromodomains possess a "keyhole style" pocket due to a larger aromatic gatekeeper residue that can only accommodate one acetyllysine group in the canonical binding site 19, 36 . Thus, in ITC binding assays and crystallization studies the BRD9 bromodomain interacts with the di-acetylated histone ligand by coordinating the H4K5ac group in one bromodomain with the H4K8ac site bound to a second bromodomain module (PDBID: 4YYI) 19 .
A related structure shows that the BRPF1 bromodomain binds to the histone H4K5acK8ac in an identical manner as an apparent dimer (PDBID: 5FFW) 12 . However, this is likely due to crystal packing effects caused by the crystallization conditions used for solving the crystal structure, since our ITC binding data and analytical ultracentrifugation analysis of the BRPF1 bromodomain support monomeric coordination of both mono-and di-acetylated histone ligands in solution. Also, unlike the BET proteins, which contain two adjacent bromodomain modules 51 , the BRPF1 protein has only one bromodomain, and this protein functions as a single subunit within the MOZ/MORF HAT complexes 4, 10 . Thus, the BRPF1 bromodomain is likely to be monomeric in its biologically active form.
Histone H4 can be post-translationally modified at multiple positions and is frequently acetylated at lysine 5, 8, 12 and 16. It also often carries a phosphorylation mark on serine 1, as well as methyl groups on arginine 3 and lysine 20 52 . The SET-domain methyltransferases performs methylation of lysine on the histone tails 53 , which can be mono-, di-or tri-methylated. Lysine at position 5 and 12 of histone H4 can also be methylated 32, 54 . Since acetylation at lysine 5 and 12 on histone H4 are the positions the BRPF1 bromodomain binds with highest affinity, we tested the effect tri-methylation at these sites would have on bromodomain binding. Our results demonstrated that tri-methylation of H4K5 reduced the binding affinity of the BRPF1 bromodomain for the H4K12ac ligand, while tri-methylation of H4K12 did not have a significant impact on the recognition of H4K5ac. We also characterized how phosphorylation of serine 1 modulates the acetyllysine binding activity of the BRPF1 bromodomain and showed that this mark has an inhibitory effect on recognition of H4K5ac. Histone phosphorylation has previously been linked to DNA damage repair mechanisms 55 , and H4S1phos is known to be enriched 20-to 25-fold in nucleosomes that are located adjacent to double strand breaks 56 . The impact of modifications adjacent to acetyllysine recognition sites may be biologically relevant to BRPF1's function in recruiting the MOZ HAT tetrameric complex to distinct sites on chromatin depending on the epigenetic landscape. For example, phosphorylation of histone H4S1 at sites of DNA damage could function to prevent or delay the transcriptional activation signaling by acetylation modifications until the genetic information can be repaired. Therefore, our study represents an important first step in understanding how the BRPF1 bromodomain is able to recognize and bind di-acetyllysine on the histone tail, and how cross-talk among adjacent marks influences its activity.
To delineate the acetyllysine binding site on BRPF1 bromodomain we used NMR chemical shift perturbation data to identify the residues involved in di-acetyllysine recognition, and to observe whether residues outside the canonical acetyllysine binding pocket are important for coordinating the second acetyllysine modification. Interestingly, our NMR titration analysis displayed a similar trend in the chemical shift perturbations observed for the mono-versus the di-acetylated histone ligands. The reason for this could be two-fold: Firstly, in the present invitro condition, the BRPF1 bromodomain shows a similar binding pocket for the mono-versus the di-acetylated H4 histone ligands, thus indicating that there may be other mechanisms involved in more specific interactions of the BRPF1 bromodomain with the di-acetylated H4 histone tail in-vivo. BRD7, which shows high structural similarity to BRPF1, has also been reported to lack specificity towards histone ligands in in-vitro conditions 57 . Secondly, the second acetyllysine is likely making transient side chain interactions with certain residues surrounding the canonical BRPF1 bromodomain binding pocket not readily detected by our backbone amide NMR titrations. A similar observation was made for the BRDT BD1 bromodomain, which interacts with the di-acetylated H4K5acK8ac histone ligand via the methyl groups of the hydrophobic residues lining the bromodomain pocket 36 .
Large chemical shift perturbations for the N83 residue of BRPF1 bromodomain were consistently observed in our NMR titration analysis confirming the importance of this residue in the coordination of acetylated H4 histone peptides. When compared to the crystal structure of the BRDT BD1 in complex with H4K5acK8ac (1-20) (PDBID:2WP2), the BRPF1 bromodomain (PDBID:2D9E) seems to adapt a similar binding environment for the H4K5ac moiety as the BD1 bromodomain (Supplementary Figure S2) . Mainly, in the BRDT BD1, residues V55, L62 and C104 are known to be involved in hydrophobic interactions with the H4K5ac moiety in addition to the hydrogen bond with N108 36 . In BRPF1, these correspond to residues V32, V37 and C79 as well as to the conserved N83 residue, based on their structural alignment (RMSD = 1.755) determined using the protein structure comparison service PDBeFold at the European Bioinformatics Institute (http://www.ebi.ac.uk/msd-srv/ssm) 58 . The same residues also showed chemical shift perturbations for di-acetylated histone H4 ligands (H4K5acK8ac and H4K5acK12ac) indicating that the K5ac group interacts with the BRPF1 bromodomain in the same position regardless of the second acetyllysine site on the histone.
We introduced additional mutations into the BRPF1 bromodomain binding pocket to test hypotheses based on previous studies of acetyllysine coordination by other related bromodomains [39] [40] [41] [42] . I27 is found in the BRPF1 "NIF Shelf", which is important for ligand selectivity 59 . L34, E36 and V37 are all located in the flexible ZA loop adjacent to the acetyllysine binding site, which is predicted to be important for increasing the on-rate of histone tail binding 41 . N83 is the universally conserved asparagine residue involved in coordination of the acetyllysine modification on histones 59 . I88 is adjacent to the 'gatekeeper' residue F89 (unassigned) that lines the acetyllysine binding pocket. We used ITC experiments with a subset of the histone H4 peptides to compare the binding activity of the mutant BRPF1 bromodomain proteins with the affinities measured for the WT BRPF1 bromodomain ( Table 2) . Circular dichroism spectroscopy studies were also carried out to ensure that the mutations had no significant effect on the overall structure of the BRPF1 bromodomain. Residue E36 in the BRPF1 bromodomain showed the largest chemical shift perturbation upon addition of either mono-or di-acetylated histones. Alignment of the apo crystal structure of the BRPF1 bromodomain (PDBID: 2D9E) with BRPF1 bromodomain structures in combination with the H2AK5ac and H4K12ac ligands (PDBIDs: 4QYL and 4QYD) 42 , demonstrate that the E36 residue does not contact the histone ligands directly, but undergoes a large conformational change as part of the ZA loop to accommodate peptide binding. Mutation of E36 to alanine does not significantly alter the binding affinity of the BRPF1 bromodomain with the H4K5ac (1-10) ligand, but it does decrease the interaction of BRPF1 with the di-acetylated histone H4K5acK8ac
(1-10) ligand ( Table 2 ), suggesting it may be an important contact for the K8ac moiety. A recent study investigating the intermolecular contacts between the related ATAD2 family IV bromodomain and the H4K5acK12ac ligand found that residue E1017, which is equivalent to E36 in the BRPF1 bromodomain, comes within 5Å of H4K8 in molecular dynamic simulations of the holo complex 41 .
A prior study on the ATAD2 bromodomain found the H3K14ac ligand bound to a secondary site distal from the canonical bromodomain binding site 39 . In this ATAD2 structure (PDBID: 4TT4), two residues were involved in coordination of the acetyllysine moiety, R1005 and H1076.
H1076 is equivalent to T24 in the BRPF1 bromodomain. The T24A mutant showed a two-fold stronger binding affinity for the H4K5ac (1-10) ligand than the wild-type BRPF1 bromodomain, while also having a weaker interaction with the H4K5acK8ac (1-10) ligand. This suggests that residue T24 plays some role in coordinating either the K5ac or the K8ac in the di-acetylated histone ligand. Notably, mutation of either K81 to alanine significantly weakened the interaction of the BRPF1 bromodomain for the H4K5acK8ac ligand, also indicating a role for this residue in coordination of this di-acetylated histone ligand. However, the N26A and E30A mutations resulted in modest changes in the binding affinity of the BRPF1 bromodomain for the histone ligands, suggestive of the neutral role of these residues in acetyllysine binding. Similarly, the R91A mutation resulted in slightly stronger binding interactions of the BRPF1 bromodomain with both the mono-and di-acetyllysine ligands. When the histone peptides contain two acetyllysine groups it is possible for either group to be inserted into the canonical bromodomain binding pocket. One possible reason we observed an increase in binding affinity of the mutant BRPF1 bromodomain proteins with the di-acetyllysine ligands could be because their binding is now stabilized in one orientation over the other. In a di-acetylated ligand, not only is each acetyllysine group able to insert into the canonical binding pocket, but the peptide can bind in different orientations (e.g. from N-to C-terminal or vice versa) across the surface of the bromodomain binding pocket. Thus, by altering the BRPF1 bromodomain surface contacts with histone residues surrounding the primary acetyllysine inserted into the canonical binding pocket, some of our mutations may be preferentially selecting for one orientation over another, thereby stabilizing the ligand binding interaction with both mono-and di-acetylated histone peptides.
Overall, our NMR titration and mutagenesis data demonstrate that the acetyllysine binding pocket in BRPF1 bromodomain binds a variety of acetylated histone ligands with a conserved binding mechanism, and that increased sidechain and/or hydrophobic interactions are involved in the coordination of the second acetyllysine group, thus resulting in stronger binding affinities for the di-acetylated histone ligands.
Previous studies have identified ordered waters in the bromodomain binding pocket that coordinate the acetyllysine modification 42, 60 . One of these waters (w1) connects the carbonyl oxygen of the acetyllysine moiety to the hydroxyl group of Y40. Y40 is located in the αAZ loop of the bromodomain module and sequence alignment reveals that this tyrosine is conserved in all but two of the human bromodomain proteins 4 , thus this residue is even more highly conserved than the binding site asparagine residue that contacts the acetyllysine group directly. Our conservative mutation of this residue to phenylalanine demonstrated that not only is Y40 essential for water coordination, but it also plays an important structural role supporting the three-dimensional fold of the bromodomain module. Our results shed light on why Y40 is the most highly conserved amino acid residue found in human bromodomains.
In summary, we characterized the di-acetylated histone ligands of the BRPF1 bromodomain, and our results demonstrate that the BRPF1 bromodomain is able to recognize multiple acetyllysine combinations on the histone tail. Our results also confirm that cross-talk between PTMs on histone tail peptides can modulate acetyllysine recognition by the BRPF1 bromodomain. This research provides further insights into how the BRPF1 bromodomain recruits its partners in the MOZ/MORF HAT complexes to chromatin, with different combinations of PTMs either promoting or inhibiting the binding interaction. Chromosomal translocations of the MOZ HAT are associated with acute myeloid leukemia, and fusion of MOZ with TIF2, CBP and p300 are thought to drive leukemogenesis through aberrant acetylation [61] [62] [63] . Understanding how cross-talk influences bromodomain binding specificity and affinity is an important first step to connect how epigenetic changes contribute to the etiology of disease, and may provide new mechanisms for therapeutic intervention in the treatment of AML and other diseases.
MATERIALS AND METHODS
Plasmid construction
The cDNA coding for human BRPF1 was kindly provided to us by Dr. Xiang-Jiao Yang at McGill University. Residues 629-742 encoding the BRPF1 bromodomain region were amplified using PCR and subsequently cloned into the pDEST15 vector encoding an N-terminal glutathione S-transferase (GST) tag. The Gateway cloning technology (Invitrogen) was used for cloning the BRPF1 bromodomain as described previously 31 . BRPF1 bromodomain mutants T24A, N26A, E30A, E36A, Y40F, K81A and R91A were generated using the QuikChange ® mutagenesis procedure (Stratagene) as described previously 64 . All of the mutants were also cloned into the pDEST15 vector and the DNA sequences of the wild-type (WT) and mutant proteins were verified by Eurofins Genomics. The WT and mutant plasmids were then transformed into Escherichia coli Rosetta TM 2(DE3)pLysS competent cells (Novagen) for protein expression.
BRPF1 bromodomain expression and purification
E. coli Rosetta TM 2(DE3)pLysS cells expressing the WT and mutant GST-tagged BRPF1 bromodomain were grown in terrific broth (TB) at 37°C until an OD600 of 1.0 was reached. The 
Histone peptide synthesis
Histone peptides containing unique acetylated and/or methylated lysine, as well as phosphorylated serine modifications were synthesized by GenScript and purified by HPLC to 98% purity. The correct composition of each peptide was confirmed by mass spectrometry.
Isothermal titration calorimetry
ITC measurements were conducted using a MicroCal iTC200 instrument (Malvern Panalytical).
All experiments were performed at 5°C. The BRPF1 WT and mutant bromodomain proteins were dialyzed into ITC buffer containing 20 mM NaH2PO4 pH 7.0, 150 mM NaCl and 1 mM 
Circular dichroism spectroscopy
Circular Dichroism (CD) spectra were recorded on a JASCO J-815 CD Spectrometer (JASCO, Japan) at 25°C in a 1.6 cm cell. BRPF1 bromodomain WT and mutant proteins were dialyzed in CD buffer containing 50 mM NaH2PO4 pH 7.0 and 50 mM NaCl and then diluted to between 0.1 µM and 0.5 µM concentration. CD spectra were measured from 199 nm to 260 nm. Two spectra were measured and averaged for each WT and mutant bromodomain protein sample. The spectra were analyzed using the K2D3 structure prediction software 65 66 to determine the percent αhelical and β-sheet content for the WT and each of the mutant BRPF1 bromodomain proteins.
NMR spectroscopy
Chemical shift perturbation experiments were performed using 0.4 mM of uniformly 15 for all samples were run at 25°C and NMR data collected as described previously 31 . Normalized chemical shift changes were calculated as described in 67 Residues whose chemical shift change was greater than 0.5σ were colored yellow, while residues with chemical shift changes greater than 1σ and 2σ were colored orange and red, respectively.
The backbone resonance assignments for the BRPF1 bromodomain were completed as previously as described in 31 .
Analytical ultracentrifugation
For all AUC experiments, samples of the WT and mutant BRPF1 bromodomain proteins were prepared at an OD280 of 0.6 (80.5 μM) in AUC buffer containing 50 mM NaH2PO4 pH 7.0, 50 mM NaCl and 1 mM TCEP. The BRPF1 bromodomain protein alone, and in combination with unmodified histone H4 peptide residues 1-15 mixed in a 1:1 molar ratio, were included as controls. All other acetylated histone peptides (H4K5ac 1-15, H4K12ac 1-15, H4K8ac 1-10, 69 . Optimization was performed by 2-dimensional spectrum analysis (2DSA) 70 with simultaneous removal of time-and radially-invariant noise contributions 71 . After inspection of the 2DSA solutions, the fits were further refined using the parametrically constrained spectrum analysis (PCSA) 72 , coupled with Monte Carlo analysis to measure confidence limits for the determined parameters 73 . The calculations are computationally intensive and were carried out on high performance computing platforms 74 Email address: karen.glass@acphs.edu Present Addresses †If an author's address is different than the one given in the affiliation line, this information may be included here.
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